Xilio Therapeutics Immuno-Oncology Biotech Prices $50 Million Offering With Multiple Warrants, Shares Drop 26%

Xilio Therapeutics Inc. announced a proposed public offering priced at $50 million, which includes multiple warrant series (A, B, and C). The offering has led to a sharp decline in Xilio's pre-market stock price, falling by 26.2%. The company operates in the immuno-oncology biotechnology sector. Separately, BigBear.ai Holdings Inc. is considering a stock offering that could raise up to $150 million, with its shares down 4.1% pre-market. Oklo Inc. also saw a 6% drop in its stock following news of a $1 billion mixed shelf offering.